16874-70-7 Usage
General Description
H-GLN-ALA-OH, also known as L-Glutaminyl-L-alanine, is a dipeptide composed of two amino acids, L-Glutamine and L-Alanine, connected by a peptide bond. This chemical compound is significant due to its role as a constituent in many proteins and in biological reactions in the body. The 'H' in the name indicates the presence of a hydrogen atom at the start of the compound, while 'OH' at the end indicates a hydroxyl group. H-GLN-ALA-OH is generally used in the field of biochemistry for research purposes. It is soluble in water and should be stored in a cool, dry place to maintain its chemical stability.
Check Digit Verification of cas no
The CAS Registry Mumber 16874-70-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,8,7 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 16874-70:
(7*1)+(6*6)+(5*8)+(4*7)+(3*4)+(2*7)+(1*0)=137
137 % 10 = 7
So 16874-70-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)
16874-70-7Relevant articles and documents
Disulfide bridged cyclic peptides containing a cgridri sequence useful in control of hypertension
-
, (2014/02/10)
Disulfide bridged cyclic peptides are described which are preferably 13 to 20 amino acid residues in length and which include the endocyclic sequence cys-gly-arg-ile-asp-arg-ile. Peptides of this class are selective for and show picomolar-range affinity for the non-guanyl cyclase-coupled atrial peptide receptor. Affinity for this receptor is associated with potentiation of the mean arterial pressure response to atrial peptide and these peptides are therefore useful in control of hypertension. Peptides of most interest are of the formula wherein X1 is the peptidic fragment ser-ser; wherein X2 is a peptidic fragment selected from gly-ser-gly-leu, gly-ala-gly-leu and gly-leu; wherein X3 is the peptidic fragment asn-ser-phe-arg; wherein m is zero or one, n is one and r is one; and wherein A represents an amino terminus or its pharmaceutically--acceptable salt, and B represents a carboxyl terminus or its pharmaceutically-acceptable ester, amide or salt.
